Back to results
US 2026/0016489 A1Published application
Methods for treating and diagnosing systemic lupus erythematosus
AssigneeExagen Inc.
InventorsThierry Dervieux, Derren Barken
Life of this patent
Estimating the term…
Abstract
Biomarkers, such as erythrocyte-bound C4d. B-lymphocyte-bound C4d. anti-nuclear antibody. Sjögren's syndrome type B antigen, Scl-70 antibody. Jo-1 antibody, and anti-centromere protein B. can be used to diagnose. prognose, monitor, and treat subjects having systemic lupus erythematosus.
Claims19
A method of treating systemic lupus erythematosus in a human subject in need thereof, the method comprising:
- (a) receiving a systemic lupus erythematosus risk score for the human subject, wherein the systemic lupus erythematosus risk score is produced by a method comprising the steps of:
- (i) log normalizing a level of erythrocyte-bound C4d (EC4d) marker to produce a log normalized level of EC4d marker and multiplying the log normalized level of EC4d marker by a predetermined weighting coefficient to produce a weighted score for EC4d marker, wherein the level of EC4d marker is detected in a blood sample obtained from the human patient;
- (ii) log normalizing a level of B-lymphocyte-bound C4d (BC4d) marker to produce a log normalized level of BC4d marker and multiplying the log normalized level of BC4d marker by a predetermined weighting coefficient to produce a weighted score for BC4d marker, wherein the level of BC4d marker is detected in a blood sample obtained from the human patient;
- (iii) multiplying a level of anti-nuclear antibody (ANA) by a predetermined weighting coefficient to produce a weighted score for ANA, wherein the level of ANA is detected in a blood sample obtained from the human patient;
- (iv) adjusting the level of an antibody selected from the group consisting of anti-Sjögren's syndrome type B antigen antibody, anti-Scl-70 antibody, anti-Jo-1 antibody, anti-centromere protein B antibody, and a combination of two or more thereof to produce a weighted score for the antibody selected from the group consisting of anti-Sjögren's syndrome type B antigen antibody, anti-Scl-70 antibody, anti-Jo-1 antibody, anti-centromere protein B antibody, and a combination of two or more thereof;
- wherein the level of the antibody selected from the group consisting of anti-Sjögren's syndrome type B antigen antibody, anti-Scl-70 antibody, anti-Jo-1 antibody, anti-centromere protein B antibody, and the combination of two or more thereof are detected in a blood sample obtained from the human patient;
- (v) combining the weighted score for the antibody selected from the group consisting of anti-Sjögren's syndrome type B antigen antibody, anti-Scl-70 antibody, anti-Jo-1 antibody, anti-centromere protein B antibody, and the combination of two or more thereof to produce an antibody specificity component score;
- (vi) combining the weighted score for EC4d marker, the weighted score for BC4d marker, the weighted score for ANA, and the antibody specificity component score to produce the systemic lupus erythematosus risk score;
- wherein the systemic lupus erythematosus risk score does not include a score for a level of double-stranded DNA antibody;
- (b) diagnosing the human subject with systemic lupus erythematosus based on the systemic lupus erythematosus risk score, prognosing the human subject with systemic lupus erythematosus based on the systemic lupus erythematosus risk score, determining a level of systemic lupus erythematosus disease activity in the human subject based on the systemic lupus erythematosus risk score, or monitoring systemic lupus erythematosus disease activity in the human subject based on the systemic lupus erythematosus risk score;
- and
- (c) treating the human subject from step (b) with an effective amount of cyclophosphamide, a corticosteroid, mycophenolate, methotrexate, azathioprine, leflunomide, belimumab, or hydroxychloroquine.
9 more elements
A method of treating systemic lupus erythematosus in a human subject in need thereof, the method comprising:
- (a) selecting the human subject having a diagnosis of systemic lupus erythematosus based on a systemic lupus erythematosus risk score, wherein the systemic lupus erythematosus risk score is produced by a method comprising the steps of:
- (i) log normalizing a level of erythrocyte-bound C4d (EC4d) marker to produce a log normalized level of EC4d marker and multiplying the log normalized level of EC4d marker by a predetermined weighting coefficient to produce a weighted score for EC4d marker, wherein the level of EC4d marker is detected in a blood sample obtained from the human patient;
- (ii) log normalizing a level of B-lymphocyte-bound C4d (BC4d) marker to produce a log normalized level of BC4d marker and multiplying the log normalized level of BC4d marker by a predetermined weighting coefficient to produce a weighted score for BC4d marker, wherein the level of BC4d marker is detected in a blood sample obtained from the human patient;
- (iii) multiplying a level of anti-nuclear antibody (ANA) by a predetermined weighting coefficient to produce a weighted score for ANA, wherein the level of ANA is detected in a blood sample obtained from the human patient;
- (iv) adjusting the level of an antibody selected from the group consisting of anti-Sjögren's syndrome type B antigen antibody, anti-Scl-70 antibody, anti-Jo-1 antibody, anti-centromere protein B antibody, and a combination of two or more thereof to produce a weighted score for the antibody selected from the group consisting of anti-Sjögren's syndrome type B antigen antibody, anti-Scl-70 antibody, anti-Jo-1 antibody, anti-centromere protein B antibody, and a combination of two or more thereof;
- wherein the level of the antibody selected from the group consisting of anti-Sjögren's syndrome type B antigen antibody, anti-Scl-70 antibody, anti-Jo-1 antibody, anti-centromere protein B antibody, and the combination of two or more thereof are detected in a blood sample obtained from the human patient;
- (v) combining the weighted score for EC4d marker, the weighted score for BC4d marker, the weighted score for ANA, and the antibody specificity component score to produce the systemic lupus erythematosus risk score;
- wherein the systemic lupus erythematosus risk score does not include a score for a level of double-stranded DNA antibody;
- (vi) combining the weighted score for EC4d marker, the weighted score for BC4d marker, the weighted score for ANA, and the antibody specificity component score to produce the systemic lupus erythematosus risk score;
- wherein the systemic lupus erythematosus risk score does not include a score for a level of double-stranded DNA antibody;
- and
- (b) treating the human subject having the diagnosis of systemic lupus erythematosus based on the systemic lupus erythematosus risk score from (a) with an effective amount of cyclophosphamide, a corticosteroid, mycophenolate, methotrexate, azathioprine, leflunomide, belimumab, or hydroxychloroquine.
9 more elements
A method of treating systemic lupus erythematosus in a human subject in need thereof, the method comprising:
- (a) detecting a level of erythrocyte-bound C4d (EC4d) marker, a level of B-lymphocyte-bound C4d (BC4d) marker, a level of anti-nuclear antibody (ANA), a level of anti-Sjögren's syndrome type B antigen antibody, a level of anti-Scl-70 antibody, a level of anti-Jo-1 antibody, and a level of anti-centromere protein B antibody in a blood sample obtained from the human patient;
- (b) log normalizing the level of EC4d marker to produce a log normalized level of EC4d marker and multiplying the log normalized level of EC4d marker by a predetermined weighting coefficient to produce a weighted score for EC4d marker;
- (c) log normalizing the level of BC4d marker to produce a log normalized level of BC4d marker and multiplying the log normalized level of BC4d marker by a predetermined weighting coefficient to produce a weighted score for BC4d marker;
- (d) multiplying the level of ANA by a predetermined weighting coefficient to produce a weighted score for ANA;
- (e) adjusting the level of an antibody selected from the group consisting of anti-Sjögren's syndrome type B antigen antibody, anti-Scl-70 antibody, anti-Jo-1 antibody, anti-centromere protein B antibody, and a combination of two or more thereof to produce a weighted score for the antibody selected from the group consisting of anti-Sjögren's syndrome type B antigen antibody, anti-Scl-70 antibody, anti-Jo-1 antibody, anti-centromere protein B antibody, and a combination of two or more thereof;
- wherein the level of the antibody selected from the group consisting of anti-Sjögren's syndrome type B antigen antibody, anti-Scl-70 antibody, anti-Jo-1 antibody, anti-centromere protein B antibody, and the combination of two or more thereof are detected in a blood sample obtained from the human patient;
- (f) combining the weighted score for EC4d marker, the weighted score for BC4d marker, the weighted score for ANA, and the antibody specificity component score to produce the systemic lupus erythematosus risk score;
- wherein the systemic lupus erythematosus risk score does not include a score for a level of double-stranded DNA antibody;
- (g) combining the weighted score for EC4d marker, the weighted score for BC4d marker, the weighted score for ANA, and the antibody specificity component score to produce the systemic lupus erythematosus risk score;
- wherein the systemic lupus erythematosus risk score does not include a score for a level of double-stranded DNA antibody;
- (h) diagnosing the human subject with systemic lupus erythematosus based on the systemic lupus erythematosus risk score, prognosing the human subject with systemic lupus erythematosus based on the systemic lupus erythematosus risk score, determining a level of systemic lupus erythematosus disease activity in the human subject based on the systemic lupus erythematosus risk score, or monitoring systemic lupus erythematosus disease activity in the human subject based on the systemic lupus erythematosus risk score;
- and
- (i) treating the human subject from step (h) with an effective amount of cyclophosphamide, a corticosteroid, mycophenolate, methotrexate, azathioprine, leflunomide, belimumab, or hydroxychloroquine.
10 more elements
Dependencies are inferred from the claim text.